Article
The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Neuro-oncology - 1 Dec 2015
Rapkins Robert W, Wang Fan, Nguyen HuyTram N, Cloughesy Timothy F, Lai Albert, Ha Wendy, Nowak Anna K, Hitchins Megan P, McDonald Kerrie L
Abstract excerpt
BACKGROUND: Promoter methylation of O(6)-methylguanine-DNA methyltransferase (MGMT) is an important predictive biomarker in glioblastoma. The T variant of the MGMT promoter-enhancer single nucleotide polymorphism (SNP; rs16906252) has been associated with the presence of MGMT promoter methylation in other cancers. We examined the association of the T allele of rs16906252 with glioblastoma development, tumor MGMT...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
